TY  - JOUR
T1  - Adalimumab treatment in adult patients with refractory non-infectious uveitis
TT  - Dirençli non-enfeksiyöz üveitli erişkin hastalarda adalimumab tedavisinin etkinliği
AU  - Esen, Ebru
AU  - Işık, Püren
AU  - Sızmaz, Selçuk
AU  - Demircan, Nihal
PY  - 2023
DA  - July
Y2  - 2023
DO  - 10.17826/cumj.1224611
JF  - Cukurova Medical Journal
JO  - Cukurova Med J
PB  - Çukurova Üniversitesi
WT  - DergiPark
SN  - 2602-3032
SP  - 457
EP  - 462
VL  - 48
IS  - 2
LA  - en
AB  - Purpose: To assess the efficacy of adalimumab treatment in patients with refractory non-infectious uveitis.Materials and Methods: A retrospective analysis was carried out on patients with chronic non-infectious uveitis treated with adalimumab for longer than 12 months. All patients had active intraocular inflammation and were nonresponsive to other immunosuppressive agents before initiating adalimumab treatment.Results: Twenty-one patients (39 eyes) were treated with adalimumab for a mean duration of 26.2 ± 13.2 months. Eleven patients (52.4%) remained relapse-free during the treatment. In only one patient (4.8%) adalimumab was switched to another drug due to insufficient response. Adalimumab treatment was discontinued in five patients (23.8%) after an attack-free period of at least 18 months.Conclusion: Adalimumab is an effective and well-tolerated therapeutic option for patients with refractory non-infectious uveitis, to achieve and maintain disease quiescence.
KW  - Adalimumab
KW  - non-infectious uveitis
KW  - refractory uveitis
N2  - Amaç: Enfeksiyöz olmayan dirençli üveit hastalarında adalimumab tedavisinin etkinliğini değerlendirmek.Gereç ve Yöntem: Kronik non-enfeksiyöz üveit tanısıyla 12 aydan uzun süre adalimumab tedavisi alan hastalar retrospektif olarak değerlendirildi. Tüm hastalar adalimumab tedavisine başlamadan önce diğer immünosüpresif ajanlara dirençli olup aktif intraoküler inflamasyon bulgularına sahipti.Bulgular: Yirmi bir hasta (39 göz), ortalama 26.2 ± 13.2 ay süreyle adalimumab tedavisi aldı. Tedavi süresince 11 hastada (%52.4) nüks izlenmedi. Sadece bir hastada (%4,8) yetersiz yanıt nedeniyle adalimumab tedavisi başka bir ilaç ile değiştirildi. Beş hastada (%23.8) en az 18 aylık ataksız dönem sonunda adalimumab tedavisi sonlandırıldı.Sonuç: Adalimumab, dirençli enfeksiyöz olmayan üveit hastalarında remisyonu sağlamak ve sürdürmek için etkili ve iyi tolere edilen bir terapötik seçenektir.
CR  - Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, Kalogeropoulos C et al. A Focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26:2-16.
CR  - Vegas-Revenga N, Martín-Varillas JL, Calvo-Río V, González-Mazón I, Sánchez-Bilbao L, Beltrán E et al. Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. Clin Exp Rheumatol. 2022;40:142-9.
CR  - Rosenbaum JT, Bodaghi B, Couto C, Zierhut M, Acharya N, Pavesio C et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Semin Arthritis Rheum. 2019;49:438-45.
CR  - Hasegawa E, Takeda A, Yawata N, Sonoda KH. The effectiveness of adalimumab treatment for non-infectious uveitis. Immunol Med. 2019;42:79-83.
CR  - Robertson M, Liversidge J, Forrester JV, Dick AD. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2003;44:3034-41.
CR  - Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, Gómez Vidal MA, Collantes Estévez E, Ramírez Chamond R et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251-5.
CR  - Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol. 2015;60:575-89.
CR  - Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785-96.e3.
CR  - Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932-43.
CR  - Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183-92.
CR  - Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509-16.
CR  - Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017;135:511-8.
CR  - Lee FF, Foster CS. Pharmacotherapy of uveitis. Expert Opin Pharmacother. 2010;11:1135-46.
CR  - Hiyama T, Harada Y, Kiuchi Y. Efficacy and Safety of adalimumab therapy for the treatment of non-infectious uveitis: Efficacy comparison among uveitis aetiologies. Ocul Immunol Inflamm. 2022;30:951-8.
CR  - Touhami S, Diwo E, Sève P, Trad S, Bielefeld P, Sène D et al. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin Biol Ther. 2019;19:477-90.
CR  - Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125:1075-87.
CR  - Mercier AE, Ribeiro E, Korobelnik JF, Delyfer MN, Rougier MB. Efficacy of anti-TNF-α therapy for the treatment of non-infectious uveitis: a retrospective study of 21 patients. Ocul Immunol Inflamm. 2018;26:477-84.
CR  - Tang Lee Say TL, Yang V, Fingret JM, Zagora S, Symes R, Younan C et al. Adalimumab in patients with vision-threatening uveitis: real-world clinical experience. BMJ Open Ophthalmol. 2021;6:e000819.
CR  - Dobner BC, Max R, Becker MD, Heinz C, Veltrup I, Heiligenhaus A et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97:134-8.
CR  - Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575-81.
CR  - Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97:481-6.
CR  - Park SE, Jun JW, Lee DH, Lee SC, Kim M. The effect of adalimumab in korean patients with refractory noninfectious uveitis. Yonsei Med J. 2021;62:177-81
UR  - https://doi.org/10.17826/cumj.1224611
L1  - https://dergipark.org.tr/tr/download/article-file/2853958
ER  -